Anti-CD38 therapy impairs SARS-CoV-2 vaccine response against Alpha and Delta variants in Multiple Myeloma patients
| Autor: | Henriquez, S., Zerbit, J., Bruel, T., Ouedrani, A., Planas, D., Deschamps, P., Staropoli, I., Hadjadj, J., Varet, B., Ermak, N., Bouscary, D., Willems, L., Fouquet, G., Decroocq, J., Franchi, P., Deau-Fischer, B., Terrier, B., Tamburini, J., Chatenoud, L., Schwartz, O., Vignon, M. |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male Immunity Cellular anti-CD38 therapy IFNγEliSpot SARS-CoV-2 COVID-19 Middle Aged ADP-ribosyl Cyclase 1 Immunity Humoral multiple myeloma Antineoplastic Agents Immunological Immunogenicity Vaccine SARS-CoV-2 vaccine Humans neutralizing antibodies Female Prospective Studies Letter to Blood BNT162 Vaccine Aged |
| Zdroj: | Blood |
| ISSN: | 1528-0020 0006-4971 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|